KOGENATE-FS for Injection 500 iuvial Singapūras - anglų - HSA (Health Sciences Authority)

kogenate-fs for injection 500 iuvial

bayer (south east asia) pte ltd - antihemophilic factor (recombinant) sucrose formulated - injection, powder, lyophilized, for solution - 500iu/vial - antihemophilic factor (recombinant) sucrose formulated 500iu/vial

RECOMBIVAX HB (hepatitis b vaccine- recombinant injection, suspension Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

recombivax hb (hepatitis b vaccine- recombinant injection, suspension

merck sharp & dohme llc - hepatitis b virus subtype adw hbsag surface protein antigen (unii: xl4hlc6jh6) (hepatitis b virus subtype adw hbsag surface protein antigen - unii:xl4hlc6jh6) - hepatitis b virus subtype adw hbsag surface protein antigen 5 ug in 0.5 ml - recombivax hb® [hepatitis b vaccine, recombinant] is indicated for prevention of infection caused by all known subtypes of hepatitis b virus. recombivax hb is approved for use in individuals of all ages. recombivax hb dialysis formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older. do not administer recombivax hb to individuals with a history of severe allergic or hypersensitivity reactions (e.g. , anaphylaxis) after a previous dose of any hepatitis b-containing vaccine or to any component of recombivax hb, including yeast [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively. there are no adequate and well-controlled studies designed to evaluate recombivax hb in pregnant women. available post-approval data do not suggest an in

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets blister pack Australija - anglų - Department of Health (Therapeutic Goods Administration)

biktarvy bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets blister pack

gilead sciences pty ltd - bictegravir sodium, quantity: 52.45 mg (equivalent: bictegravir, qty 50 mg); tenofovir alafenamide fumarate, quantity: 28.04 mg (equivalent: tenofovir alafenamide, qty mg); emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - biktarvy is indicated for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are antiretroviral therapy (art)-na?ve or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen at the start of therapy with no history of treatment failure, and no known substitutions associated with resistance to the individual components of biktarvy.

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets bottle Australija - anglų - Department of Health (Therapeutic Goods Administration)

biktarvy bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets bottle

gilead sciences pty ltd - bictegravir sodium, quantity: 52.45 mg (equivalent: bictegravir, qty 50 mg); tenofovir alafenamide fumarate, quantity: 28.04 mg (equivalent: tenofovir alafenamide, qty mg); emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - biktarvy is indicated for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are antiretroviral therapy (art)-na?ve or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen at the start of therapy with no history of treatment failure, and no known substitutions associated with resistance to the individual components of biktarvy.

HBVAXPRO INJECTION 5 mcg0.5 ml Singapūras - anglų - HSA (Health Sciences Authority)

hbvaxpro injection 5 mcg0.5 ml

msd pharma (singapore) pte. ltd. - hepatitis b surface antigen (recombinant) - injection - 5 mcg/0.5 ml - hepatitis b surface antigen (recombinant) 5 mcg/0.5 ml

ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet Australija - anglų - Department of Health (Therapeutic Goods Administration)

odefsey emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 28.04 mg; rilpivirine hydrochloride, quantity: 27.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; croscarmellose sodium; polysorbate 20; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - odefsey is indicated as a complete regimen for the treatment of hiv-1 infection in adults and adolescents (12 years and older with body weight at least 35 kg) with plasma hiv-1 rna <= 100,000 copies/ml at the start of therapy. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of odefsey.

Rasagiline Vancombex Tablets 1mg Malta - anglų - Medicines Authority

rasagiline vancombex tablets 1mg

combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - rasagiline - tablet - rasagiline 1 mg - anti-parkinson drugs

COMBIVIR Izraelis - anglų - Ministry of Health

combivir

glaxo smith kline (israel) ltd - lamivudine; zidovudine - film coated tablets - lamivudine 150 mg; zidovudine 300 mg - lamivudine - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

BEXSERO Jungtiniai Arabų Emyratai - anglų - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

bexsero

recombinant neisseria meningitidis group b fhbp fusion protein(rp936-741), recombinant neisseria meningitidis group b nada protein(rp961c ), recombinant neisseria meningitidis group b nhba fusion protein(rp287-953), outer membrane vesicles (omv) from neisseria meningitidis group b strain nz98/254 measured as amount of total protein containing the pora p1.4 -

NAVELBINE vinorelbine 50mg/5mL (as tartrate) injection vial Australija - anglų - Department of Health (Therapeutic Goods Administration)

navelbine vinorelbine 50mg/5ml (as tartrate) injection vial

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.